ESO Lymphoma Course

 

ESO Lymphoma Course
Avatar

The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment, TP53 Status, 2nd Line Setting and MRD

By ESO Lymphoma Course FEATURING Davide Rossi
By ESO Lymphoma Course FEATURING Davide Rossi
169 views
August 19, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Videos
18:40
ESO Lymphoma Course

Chemo-free Therapy for Follicular Lymphoma - Rituximab as Single Age…

Feat. E. Zucca
39:10
ESO Lymphoma Course

Hodgkin Lymphoma - Kairos vs. Chronos Principle & New Active Age…

Feat. P. Johnson
14:43
ESO Lymphoma Course

The Mutational Landscape of CLL: Diagnosis, Survival, and Watch and …

Feat. D. Rossi
19:04
ESO Lymphoma Course

The Mutational Landscape of CLL: 1st line, Fixed Duration Treatment,…

Feat. D. Rossi
22:43
ESO Lymphoma Course

R-CHOP Therapy for 61 y/o Male with Stage IIIB bulky DLBCL & Avo…

Feat. A. Moccia
23:01
ESO Lymphoma Course

Treatment of 58 y/o Male with Stage IV B Marginal Zone lLymphoma : T…

Feat. A. Moccia
31:37
ESO Lymphoma Course

Efficacy and Safety of Anti-CD19 CAR T-cell Therapy in B-cell Lympho…

Feat. S. Neelapu
26:51
ESO Lymphoma Course

Management of Mantle Cell Lymphoma: Prognostic Factors, Younger vs. …

Feat. S. Rule
31:53
ESO Lymphoma Course

Update on Primary and Secondary CNS Lymphoma: Diagnosis, Treatment O…

Feat. T. Batchelor
18:27
ESO Lymphoma Course

Update on Waldenstrom's Macroglobulinemia: Somatic Mutation in …

Feat. B. Gerber
22:17
ESO Lymphoma Course

First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CH…

Feat. A. Davies
18:20
ESO Lymphoma Course

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezom…

Feat. A. Davies
09:10
ESO Lymphoma Course

Evolution of Cancer Therapies: Molecular Selection of Patients, Hist…

Feat. A. Stathis
09:22
ESO Lymphoma Course

Main Phases of Clinical Drug Development, New Trials Designs (Umbrel…

Feat. A. Stathis
07:54
ESO Lymphoma Course

Current and Future Drug Development in DLBCL: Review of Methodology,…

Feat. A. Stathis
21:39
ESO Lymphoma Course

Case of 58 y/o Male with IgM Multiple Myeloma and Amyloidosis: Disea…

Feat. B. Gerber
11:39
ESO Lymphoma Course

Treatment of 57 y/o Male with B-Lymphoblastic Lymphoma

Feat. B. Gerber
32:00
ESO Lymphoma Course

The AML Paradigm: From 3+7 for Everybody to Genetic-Driven Personali…

Feat. M. Fey
33:55
ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

Feat. A. Melnick
22:37
ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP,…

Feat. A. Melnick
16:32
ESO Lymphoma Course

Biology of T-cell Lymphoma: PTCL Molecular Characterisation & En…

Feat. L. De Leval
12:07
ESO Lymphoma Course

Biology of Anaplastic Large Cell Lymphomas (ALK+ and ALK-) & Bre…

Feat. L. de Leval
17:15
ESO Lymphoma Course

Biology of Extranodal NK/T-cell Lymphoma: Mutations and Pathways, EA…

Feat. L. de Leval
28:05
ESO Lymphoma Course

Biology of Hodgkin Lymphoma: IgV Gene Rearrangements, Factors Contri…

Feat. R. Küppers
22:48
ESO Lymphoma Course

Biology of Hodgkin Lymphoma: Relationship Between Hodgkin and Reed-S…

Feat. R. Küppers